Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Inderes illustration

Connecting investors and companies

Inderes is a hub connecting investors and listed companies. We are home to over 70 000 investors and 400 Nordic listed companies. Log in to keep up with your favourite companies!

Create an accountLog in
 
OMXHPI-0.91 %
OMXH25-0.93 %
OMXSPI-0.07 %
REMEDY+10.74 %
NANOFH+6.11 %
GRK+5.83 %
SPINN-6.00 %
QPR1V-8.33 %
PIIPPO-8.70 %
 
Recommended
Webcasts
Press releases
3rd party
ShowingAll regions, All content types
CEO sells shares to finance home purchase
Analyst Comment16 hours ago by
Christoffer Jennel

CEO sells shares to finance home purchase

HomeMaid announced on Friday that its CEO, Stefan Högkvist, has sold 280,000 shares (at SEK 29 per share) in the company. The total value of the transaction amounted to 8.1 MSEK. Following this transaction, Stefan Högkvist’s holding in HomeMaid amounts to 155,000 shares (~0.8% of outstanding shares) and call options corresponding to 350,000 shares.

HomeMaid
Inderes Group - Strong CMD season backs clear beat in November - SEB
Research19 hours ago

Inderes Group - Strong CMD season backs clear beat in November - SEB

Inderes delivered solid monthly sales in November with sales increasing by 15% y/y. The strong growth owes to improved CMD activity. The sales beat our estimate by EUR 0.2m, which was the case also in October. Consequently, after two months of reporting in Q4 the sales run-rate is some EUR 0.4m above our current projection. Our positive read-x is also supported by the fact that Inderes has managed to win CMDs also in Sweden.

Inderes
A sit-down with CEO Remco Westermann37:35
Video23 hours ago by
Christoffer Jennel

A sit-down with CEO Remco Westermann

In this interview, we sit down with Verve Group’s CEO Remco Westermann reflecting on 2025 and the path forward.

Verve Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Remedy's new game Control Resonant scheduled for release already in 2026
Analyst Commentyesterday by
Atte Riikola

Remedy's new game Control Resonant scheduled for release already in 2026

The game will be released in 2026, which is earlier than our current forecast (H1'27).

Remedy Entertainment
Spinnova: ARMEDANGELS signed a non-binding letter of intent for securing SPINNOVA® fiber
Analyst Commentyesterday by
Antti Viljakainen, Kaisa Vanha-Perttula

Spinnova: ARMEDANGELS signed a non-binding letter of intent for securing SPINNOVA® fiber

We believe this new brand partnership is a positive addition to Spinnova's network of partners and will support the long-term outlook for demand of fiber produced using the company's technology. However, we do not believe that the agreement will have a significant financial impact in the near future. Reducing technology investment and production costs and identifying technology investment partners continue to play a key role in the company's commercialization efforts.

Spinnova
Faron drew down the second tranche of the convertible bond
Analyst Commentyesterday by
Antti Siltanen

Faron drew down the second tranche of the convertible bond

Of the 35 MEUR convertible bond financing, 25 MEUR has now been drawn.

Faron Pharmaceuticals
Scanfil: Accelerating earnings growth starts to attract
Researchyesterday by
Antti Viljakainen

Scanfil: Accelerating earnings growth starts to attract

However, with the valuation decrease due to the recent around 10% price drop (2026e: P/E 12x), we feel the expected return has improved and risen slightly above the required return. In our view, Scanfil also offers an attractive investment story of profitable growth in the longer term.

Scanfil
Sanoma: On the verge of accelerating earnings growth
Research20 hours ago by
Petri Gostowski

Sanoma: On the verge of accelerating earnings growth

We have reviewed our estimates following Sanoma's Capital Markets Day and updated financial targets.

Sanoma
Aiforia as an Investment | Life Science Night Dec  9, 202531:45
Videoyesterday

Aiforia as an Investment | Life Science Night Dec 9, 2025

Jukka Tapaninen, CEO, talks about medical software company Aiforia as an investment.

Aiforia Technologies
Aiforia raised 4.2 MEUR in a directed share issue
Analyst Comment12/11/2025, 7:35 AM by
Antti Luiro, Frans-Mikael Rostedt

Aiforia raised 4.2 MEUR in a directed share issue

The share issue was expected, although it took place slightly earlier than we predicted, was smaller, and at a slightly lower valuation.

Aiforia Technologies
Scanfil completed the ADCO Circuits acquisition in the US
Analyst Comment12/11/2025, 7:47 AM by
Antti Viljakainen

Scanfil completed the ADCO Circuits acquisition in the US

Scanfil announced on Tuesday evening that it had completed the acquisition of US electronics contract manufacturer ADCO Circuits. We believe ADCO is a good strategic fit for Scanfil, and the valuation of the arrangement is also moderate, so the value creation potential of the rather small transaction seems promising.

Scanfil
Garantia takes its first step in the international markets
Analyst Comment12/11/2025, 5:40 AM by
Sauli Vilén

Garantia takes its first step in the international markets

Taaleri's guarantee insurance company Garantia announced on Wednesday that it completed its first credit risk insurance project outside Finland during the fall.

Taaleri
Puuilo Q3'25: Back on board the growth story
Researchyesterday by
Arttu Heikura

Puuilo Q3'25: Back on board the growth story

We continue to see strong long-term growth and value creation potential for the company, and the share valuation has moderated as well.

Puuilo
Endomines as an Investment | Investor Day Nov. 24, 202517:27
Video12/10/2025, 11:30 AM

Endomines as an Investment | Investor Day Nov. 24, 2025

Kari Vyhtinen, CEO, talks about mining and exploration company Endomines as an investment.

Endomines Finland
Puuilo Q3'25 flash comment: Quarterly development in line with expectations
Analyst Comment12/10/2025, 8:36 AM by
Arttu Heikura

Puuilo Q3'25 flash comment: Quarterly development in line with expectations

The rapid sales growth is attributable to the record-fast expansion of the store network and moderate like-for-like growth.

Puuilo
Analyst Comment12/10/2025, 8:29 AM by
Sauli Vilén, Kasper Mellas

The financial sector will rank top positions on dividend lists also next spring

For financial companies, 2025 has been very positive in terms of the operating environment, with strong capital market development and stabilized interest rates. However, the performance of the companies has been varying, and many companies we follow have suffered particularly from the subdued development of alternative investment returns (new sales and performance fees).

Aktia PankkiOma SäästöpankkiAlisa PankkiNordea BankSampoMandatumAlexandria GroupTaaleriEvlieQUnited BankersCapManTitanium
Herantis Pharma as an Investment | Life Science Night Dec  9, 202528:25
Video12/9/2025, 9:11 PM

Herantis Pharma as an Investment | Life Science Night Dec 9, 2025

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma
Orion as an Investment | Life Science Night Dec. 9, 202527:26
Video12/9/2025, 9:10 PM

Orion as an Investment | Life Science Night Dec. 9, 2025

Tuukka Hirvonen, Head of Investor Relations, talks about pharmaceutical company Orion as an investment.

Orion
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/9/2025, 9:09 PM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Life Science Night | December 9, 2025
Webcast12/9/2025, 1:30 PM

Life Science Night | December 9, 2025

Welcome to follow Life Science Night on Tuesday, December 9 at 3:30 pm EET on inderesTV.

OrionAiforia TechnologiesHerantis Pharma

Latest research

Scanfil: Accelerating earnings growth starts to attract
Accumulate
Scanfil
12.12.2025
Sanoma: On the verge of accelerating earnings growth
Buy
Sanoma
12.12.2025
Puuilo Q3'25: Back on board the growth story
Accumulate
Puuilo
11.12.2025
Norrhydro Group extensive report: Light at the end of the cylinder
Accumulate
Norrhydro Group
03.12.2025
United Bankers: The sales machine is still undeperforming
Reduce
United Bankers
02.12.2025
View all

Trending

The financial sector will rank top positions on dividend lists also next spring
10.12.2025 Analyst Comment
Mallisalkku: Otimme pienen rivin Canatua salkkuun
09.12.2025 Research
Faron presented updated BEXMAB data at the ASH meeting
09.12.2025 Analyst Comment
Puuilo Q3'25: Back on board the growth story
11.12.2025 Research
Puuilo Q3'25 flash comment: Quarterly development in line with expectations
10.12.2025 Analyst Comment
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.